Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Qualified Opinion who wrote (6026)	11/20/2004 1:47:07 PM
From: david staton	Respond to of 10345

Roberga you stated two things that greatly interest me. IF Antegren indeed turns out to be a NEW CLASS of drug and THE GOLD standard for MS then all estimates ARE to conservative IMO. IF Antegren is approved for CD in 05, well, then the math gets real fun. I have a cost basis under 5 and often wonder how many shareholders are left with the same basis. The float has churned several times since the 5 level. I believe the average cost basis is much higher, especially with institutions. Currently 80% of my portfolio is Elan. It's a big bet I know. Because of that I have researched and read every article, paper, msg board and text I can find related to Elan. I believe there is more upside potential than downside risk. It will be interesting to see how the share price plays out after approval news.